|
|
|
| Recent advances in biomarkers of sarcopenia |
| 1,2Du Hongzhen, 3Sun Kejuan, 1,2Li Zengning |
| 1Department of Nutrition, First hospital of Hebei Medical University, Shijiazhuang 050031, Hebei, China; 2Hebei Provincial Key Laborato?
ry of Nutrition and Health, Shijiazhuang 050031, Hebei, China; 3Nursing Department, First hospital of Hebei Medical University, Shijia?
zhuang 050031, Hebei, China |
|
|
|
|
Abstract Sarcopenia is a progressive and widespread decline in skeletal muscle mass and strength, as well as the resulting decline
in physical fitness, quality of life, and death. There are two types of sarcopenia, primary and secondary sarcopenia. Sarcopenia is closely
related to dysactivity, falls, low bone density and metabolic disorders. It has a high incidence and a wide range of adverse results. The quality
of life of patients with sarcopenia decreases, which brings a heavy economic burden to individuals and families, and even serious adverse
effects on social public health. However, sarcopenia is often underdiagnosed in clinical practice. In recent years, based on the research on
the pathogenesis of sarcopenia, a variety of potential biomarkers have been proposed, such as myostatin, circulating C⁃terminal aggregate
protein fragments and type Ⅲ procollagen N⁃terminal peptides, etc., which are usually related to specific pathogenic mechanisms and/or
phenotypes. Effective biomarkers can promote the early diagnosis and prognosis of sarcopenia, and analyze the severity of the disease,
and the effect of treatment is evaluated, but there is currently no effective biomarker standard. This article focuses on the recent advances
in biomarkers of sarcopenia that have received high attention at home and abroad, and provide a reference for the improvement of patients
with sarcopenia. It will provide a theoretical basis to help many clinicians reasonably evaluate the patient's sarcopenia status and take
appropriate intervention measures to solve the troubles.
|
|
Received: 18 January 2022
|
|
|
|
|
|
|
